Literature DB >> 28699056

Killing Activity of Micafungin Against Candida albicans, C. dubliniensis and Candida africana in the Presence of Human Serum.

Renátó Kovács1,2, Qasem Saleh1, Aliz Bozó1, Zoltán Tóth1, Rudolf Gesztelyi3, Tamás Kardos4, Gábor Kardos1, István Takacs5, László Majoros6.   

Abstract

We compared killing activity of micafungin in time-kill experiments in RPMI-1640 with and without 50% serum against Candida albicans, Candida dubliniensis and Candida africana reference strains and clinical isolates. Killing rates (k values) were determined for each strain and concentration. In RPMI-1640 MIC ranges were 0.015-0.03, 0.015-0.03 and 0.015 mg/L against C. albicans, C. dubliniensis and C. africana, respectively. In 50% serum MIC values for the three species increased 16- to 64-fold. In RPMI-1640 micafungin was fungicidal against two of three C. albicans isolates at 16 and 32 mg/L within 14.54 h and fungistatic against all C. africana and C. dubliniensis. Fifty per cent serum significantly decreased the growth rate of C. africana, but not of the other two species; weak in vivo replication ability of C. africana was confirmed in murine model. In 50% serum micafungin at 0.25 and 1 mg/L did not inhibit any of the three species (k values were always negative). Micafungin killing rate in 50% serum at 4, 16 and 32 mg/L was significantly decreased for C. albicans, but increased for C. dubliniensis compared to RPMI-1640. Killing activity of micafungin against C. africana was comparable or higher in 50% serum than in RPMI-1640. Although micafungin is a highly protein-bound drug, it was equally effective against the species of the C. albicans complex in 50% serum at therapeutic trough concentration (4 mg/L). Both in vitro and in vivo data confirmed the low virulence of C. africana compared to the two sibling species.

Entities:  

Keywords:  Echinocandins; Killing rate; RPMI-1640; Time-kill

Mesh:

Substances:

Year:  2017        PMID: 28699056     DOI: 10.1007/s11046-017-0178-9

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  43 in total

1.  Rapid discrimination between Candida albicans and Candida dubliniensis by using real-time polymerase chain reaction.

Authors:  Ferenc Somogyvari; Ilona Doczi; Julianna Serly; Suhail Ahmad; Elizabeth Nagy
Journal:  Diagn Microbiol Infect Dis       Date:  2007-03-26       Impact factor: 2.803

2.  Antifungal activity of micafungin in serum.

Authors:  Jun Ishikawa; Tetsuo Maeda; Itaru Matsumura; Masato Yasumi; Hidetoshi Ujiie; Hiroaki Masaie; Tsuyoshi Nakazawa; Nobuo Mochizuki; Satoshi Kishino; Yuzuru Kanakura
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

3.  Micafungin therapy in a critically ill, morbidly obese patient.

Authors:  Amanda Zomp; P Brandon Bookstaver; Yasir Ahmed; J Elliot Turner; Christie King
Journal:  J Antimicrob Chemother       Date:  2011-08-02       Impact factor: 5.790

4.  Decreased Killing Activity of Micafungin Against Candida guilliermondii, Candida lusitaniae, and Candida kefyr in the Presence of Human Serum.

Authors:  Qasem Saleh; Renátó Kovács; Gábor Kardos; Rudolf Gesztelyi; Tamás Kardos; Aliz Bozó; László Majoros
Journal:  Microb Drug Resist       Date:  2017-01-10       Impact factor: 3.431

5.  Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies.

Authors:  Naoe Goto; Takeshi Hara; Hisashi Tsurumi; Kengo Ogawa; Junichi Kitagawa; Nobuhiro Kanemura; Senji Kasahara; Toshiki Yamada; Masahito Shimizu; Mitsuhiro Nakamura; Katsuhiko Matsuura; Hisataka Moriwaki
Journal:  Am J Hematol       Date:  2010-11       Impact factor: 10.047

6.  Comparison of the in vitro activity of echinocandins against Candida albicans, Candida dubliniensis, and Candida africana by time-kill curves.

Authors:  Sandra Gil-Alonso; Nerea Jauregizar; Emilia Cantón; Elena Eraso; Guillermo Quindós
Journal:  Diagn Microbiol Infect Dis       Date:  2015-02-02       Impact factor: 2.803

Review 7.  Candida africana and its closest relatives.

Authors:  Orazio Romeo; Giuseppe Criseo
Journal:  Mycoses       Date:  2010-07-28       Impact factor: 4.377

Review 8.  Echinocandins: production and applications.

Authors:  Tamás Emri; László Majoros; Viktória Tóth; István Pócsi
Journal:  Appl Microbiol Biotechnol       Date:  2013-03-06       Impact factor: 4.813

9.  Epidemiology, antifungal susceptibility, and pathogenicity of Candida africana isolates from the United Kingdom.

Authors:  Andrew M Borman; Adrien Szekely; Chistopher J Linton; Michael D Palmer; Phillipa Brown; Elizabeth M Johnson
Journal:  J Clin Microbiol       Date:  2013-01-09       Impact factor: 5.948

10.  Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period.

Authors:  Arnaldo L Colombo; Thais Guimarães; Teresa Sukienik; Alessandro C Pasqualotto; Ricardo Andreotti; Flavio Queiroz-Telles; Simone A Nouér; Marcio Nucci
Journal:  Intensive Care Med       Date:  2014-08-01       Impact factor: 17.440

View more
  2 in total

1.  Efficacy of humanized single large doses of caspofungin on the lethality and fungal tissue burden in a deeply neutropenic murine model against Candida albicans and Candida dubliniensis.

Authors:  Eszter Prépost; Zoltán Tóth; David S Perlin; Rudolf Gesztelyi; Gábor Kardos; Renátó Kovács; Fruzsina Nagy; Lajos Forgács; László Majoros
Journal:  Infect Drug Resist       Date:  2019-07-01       Impact factor: 4.003

2.  Distribution, antifungal susceptibility pattern and intra-Candida albicans species complex prevalence of Candida africana: A systematic review and meta-analysis.

Authors:  Sanaz Aghaei Gharehbolagh; Bahareh Fallah; Alireza Izadi; Zeinab Sadeghi Ardestani; Pooneh Malekifar; Andrew M Borman; Shahram Mahmoudi
Journal:  PLoS One       Date:  2020-08-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.